NASDAQ$CAI
Caris Life Sciences Inc · Q2 2026 earnings
Q2 2026 earnings · · After market close
Briefing
Caris Life Sciences Inc reported Q2 2026 revenue of $263.7 million with a near-breakeven net loss.
For the three months ended June 30, 2026, Caris generated total revenue of $263.7 million, driven by strong growth in molecular profiling services. The company achieved operating income of $26.9 million but recorded a net loss of $0.6 million after interest and other expenses. Clinical case volumes increased to approximately 59,200.
- Total revenue grew 45% year-over-year to $263.7 million, led by molecular profiling services.
- Molecular profiling services revenue reached $252.3 million, up 55% from the prior year.
- Income from operations turned positive at $26.9 million compared to a loss in Q2 2025.
- Cash, cash equivalents and restricted cash stood at $690.9 million at quarter end.
Headline financials
Revenue & EPS history
Caris Life Sciences Inc · Revenue · Quarterly
$264M
Revenue by segment
Caris Life Sciences Inc · $264M total across 2 segments · Q2 2026
- Molecular profiling services$252M—95.7%
- Pharma research and development services$11.5M—4.3%
Forward guidance
The company continues to invest in platform expansion and new solution launches while scaling operations.
Tailwinds
- Strong revenue growth and positive operating income
- Expanded product portfolio with new launches in Q2
Headwinds
- Continued net loss due to interest and other expenses
- Ongoing investments in R&D and commercial infrastructure
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 3 quarterly earnings reports
-5.8%
Avg return
Earnings day
-8.5%
Avg return
5 days after
-3.7%
Avg return
30 days after
33%
1 / 3 earnings
Positive
+7.4%
Q2 2025
Best reaction
-18.6%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -18.6% | -26.0% | -16.8% | |
| Q3 2025 | -6.3% | -20.5% | -7.4% | |
| Q2 2025 | +7.4% | +20.8% | +13.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro